AstraZeneca/Oxford COVID-19 vaccine trial paused over an illness

Organisation: Position: Deadline Date: Location:

AstraZeneca Plc said it has paused global trials, including large late-stage trials, of its experimental coronavirus vaccine due to an unexplained illness in a study participant, reports Reuters Health.

The vaccine, developed with the University of Oxford, has been described by the World Health Organisation as probably the world’s leading candidate and the most advanced in terms of development. The suspension dims prospects for an early rollout amid reports that the US was aiming for a fast-track approval before the November presidential election.

The British drug-maker said it voluntarily paused trials to allow an independent committee to review safety data, and it was working to expedite the review to minimise any potential impact on the trial timeline.

The US Food and Drug Administration defines an adverse event as one in which evidence suggests a possible relationship to the drug being tested.

According to reports, a participant based in the UK was found to have transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections. Whether the illness was directly linked to AstraZeneca’s vaccine remains unclear, the report said. AstraZeneca declined to comment on the report.

Called AZD1222, the vaccine is in late-stage clinical trials in the US, Britain, Brazil and South Africa and additional trials are planned in Japan and Russia. The trials aim to enrol up to 50,000 participants globally.

South Korea said it would look into the suspension and review its plan to participate in the manufacturing of the vaccine. “It’s not rare that clinical trials get suspended as various factors interact,” health ministry official Yoon Tae-ho told a briefing.

The decision to put the trial on hold has impacted clinical trials being conducted by other vaccine makers, which are looking for signs of similar reactions, Stat said.

The US National Institutes of Health, which is providing funding for AstraZeneca’s trial, declined to comment.

Moderna said in an emailed statement it was “not aware of any impact” to its ongoing COVID-19 vaccine study at this time.

Nine leading US and European vaccine developers pledged to uphold scientific safety and efficacy standards for their experimental vaccines despite the urgency to contain the coronavirus pandemic.

The companies, including AstraZeneca, Moderna and Pfizer, issued what they called a “historic pledge” after a rise in concern that safety standards might slip in the face of political pressure to rush out a vaccine.

The companies said they would “uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines.”

The other signatories were Johnson & Johnson, Merck & Co, GlaxoSmithKline, Novavax Inc, Sanofi and BioNTech.

 

Full Reuters Health report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.